NCT00002912 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00002912/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
valspodar [clinicaltrials_resource:26268a220d4611f075073f581a1fc16d]etoposide [clinicaltrials_resource:7cb6076e8355e089ce983cf1f80658d9]mitoxantrone hydrochloride [clinicaltrials_resource:ef7dc56be5bd26a6ea4c5656a35a1044]Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia [clinicaltrials:NCT00002912]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00002912 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00002912/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
Bio2RDF identifier
NCT00002912/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... a4df479e15ec87e5cf6d58e58b6e85
description [clinicaltrials_vocabulary:description]
Patients undergo induction the ...... s are followed every 6 months.
identifier
clinicaltrials_resource:NCT00002912/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
title
NCT00002912 arm group 08a4df479e15ec87e5cf6d58e58b6e85
@en
type
label
NCT00002912 arm group 08a4df47 ...... 4df479e15ec87e5cf6d58e58b6e85]
@en